New hope for rare brain disease: experimental drug enters mid-stage trial
NCT ID NCT07093333
First seen Apr 28, 2026 · Last updated May 13, 2026 · Updated 2 times
Summary
This study tests an experimental drug called ART5803 in 30 adults with Anti-NMDAR encephalitis (a rare brain inflammation) or related psychiatric disease. The main goal is to check the drug's safety and how well the body tolerates it, while also looking for early signs it might help control the disease. Participants will receive the drug and be monitored closely for side effects and changes in symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.